Marinol Related Published Studies
Well-designed clinical trials related to Marinol (Dronabinol)
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2008.03]
Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay. [2008.01]
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy. [2007.12.12]
Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. [2007.08.15]
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. [2007.03]
[Effects of oral cannabis and dronabinol on driving capacity] [2006.05]
Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. [2005.08]
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication] [2005.06.20]
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. [2004.07.31]
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. [2002.01.15]
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. [1997.03.01]
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. [1995.02]
Effect of dronabinol on nutritional status in HIV infection. [1993.07]
Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. [1990.12]
Well-designed clinical trials possibly related to Marinol (Dronabinol)
Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. [2009.08.01]
Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. [2009.08]
Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. [2009.08]
Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. [2009.08]
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). [2009.05]
Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. [2009.05]
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. [2009.05]
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. [2009.04]
Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. [2009.03]
Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. [2009.02]
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. [2009.02]
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. [2009.01]
Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. [2009.01]
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. [2009.01]
Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study. [2008.10.23]
Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. [2008.08.06]
Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. [2008.08]
Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. [2008.07]
Importance of screening logs in clinical trials for severe traumatic brain injury. [2008.06]
Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. [2008.04]
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. [2008.03.05]
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. [2008.03]
Nabilone for the treatment of pain in fibromyalgia. [2008.02]
Excretion of Delta9-tetrahydrocannabinol in sweat. [2008.01.30]
Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. [2008.01.26]
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. [2007.12.15]
Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. [2007.12]
Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. [2007.11]
Vaporization as a smokeless cannabis delivery system: a pilot study. [2007.11]
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. [2007.11]
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. [2007.10]
Oromucosal Delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. [2007.09]
Cannabinoid concentrations in hair from documented cannabis users. [2007.07.04]
Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. [2007.06]
Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. [2007.05]
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. [2007.03]
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. [2007.02.13]
The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults. [2007.02]
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. [2007.01]
An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. [2006.12]
Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. [2006.11.08]
High-potency marijuana impairs executive function and inhibitory motor control. [2006.10]
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. [2006.10]
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. [2006.09]
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. [2006.08]
Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. [2006.08]
Effects of nabilone, a synthetic cannabinoid, on postoperative pain. [2006.08]
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. [2006.07.20]
[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial] [2006.06]
Cannabinoids in medicine: A review of their therapeutic potential. [2006.04.21]
Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? [2006.04]
[(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [2006.04]
Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. [2006.02]
[(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [2006.01.03]
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. [2006.01]
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. [2005.09.27]
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. [2005.09]
Transdermal nicotine alters some of marihuana's effects in male and female volunteers. [2005.08.01]
Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry. [2005.06.05]
Cannabinoid influence on cytokine profile in multiple sclerosis. [2005.06]
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. [2005.06]
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. [2005.03.15]
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. [2004.12]
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. [2004.08]
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. [2004.08]
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. [2004.08]
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. [2004.05]
Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. [2004.05]
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. [2003.11.08]
Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. [2003.11]
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. [2003.10.01]
The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. [2003.09]
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. [2003.08.19]
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. [2003.07]
Effects of THC on behavioral measures of impulsivity in humans. [2003.07]
Behavioral and subjective effects of marijuana following partial sleep deprivation. [2003.06.05]
Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. [2003.05]
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. [2003.04]
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. [2003.02]
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. [2003.02]
Interaction between naltrexone and oral THC in heavy marijuana smokers. [2003.02]
Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. [2002.11]
The acute effects of tetrahydrocannabinol on auditory threshold and frequency resolution in human subjects. [2002.06]
Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. [2002.06]
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. [2002.05.14]
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. [2002.03.08]
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. [2002.03]
|
